|
 Jurors in the federal court in Wilmington, Delaware, reached their
verdict on the seventh day of a trial after rejecting Baxalta's
argument that the June 2016 patent on the treatment, Adynovate, was
invalid.
Bayer said the infringement arose from Baxalta's exclusive license
agreement with Nektar Therapeutics, a San Francisco-based company
that had done research with Bayer and knew about the patent,
including through litigation in Germany.
The award covered the period from June 14, 2016, to Nov. 30, 2018.
Jurors applied a royalty rate of 17.78 percent to a royalty base of
$872.84 million to arrive at the damages award.
Bayer is based in Leverkusen, Germany, with U.S. offices in
Whippany, New Jersey.
Baxalta was based in Illinois before Shire Plc acquired the company
in 2016. Takeda completed an acquisition of Shire for roughly $59
billion last month.
Takeda said it was disappointed with the verdict and will consider
its legal options.
"As a company, we are committed to developing and commercializing
products with the best interest of patients in mind, and without
violating the intellectual property rights of third parties," it
added.
[to top of second column] |
Bayer said it was pleased with the verdict, "which confirms the
strength of Bayer's innovation in hemophilia treatment."
Hemophilia is a mostly inherited disorder where blood fails to clot
properly. It can result in prolonged bleeding after an injury.
Shire's sales of Adynovate and other hemophilia treatments totaled
$2.23 billion in the nine months ending Sept. 30, 2018, including
$1.15 billion in the United States.
The case is Bayer Healthcare LLC v Baxalta Inc et al, U.S. District
Court, District of Delaware, No. 16-01122.
(Reporting by Jonathan Stempel in New York; editing by Bill Berkrot
and Jonathan Oatis)
[© 2019 Thomson Reuters. All rights
reserved.] Copyright 2019 Reuters. All rights reserved. This material may not be published,
broadcast, rewritten or redistributed.
Thompson Reuters is solely responsible for this content.
 |
